Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Søren S Lund

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme|December 7, 2007
Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?Allan Vaag, Søren S Lund
Clinical Chemistry|July 2, 2011
Using nonfasting lipids--hemodilution or convenience?Søren S Lund, Tonny Jensen
Diabetes Care|July 1, 2009
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et alSøren S Lund, Allan A Vaag
European Journal of Endocrinology|September 21, 2011
Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesAllan Vaag, Søren S Lund, Sørens Lund
Ugeskrift for Laeger|May 8, 2009
[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes]Bianca Hemmingsen, Søren S Lund, Allan Vaag
The New England Journal of Medicine|January 24, 2009
Follow-up of intensive glucose control in type 2 diabetesSøren S Lund, Peter Rossing, Allan A Vaag
Circulation|April 8, 2009
Letter by Lund et al regarding article, "fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events"Søren S Lund, Allan A Vaag, Tonny Jensen
European Journal of Endocrinology|April 17, 2009
Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetesBianca Hemmingsen, Søren S Lund, Jørn Wetterslev, et al.
Expert Opinion on Drug Safety|April 14, 2022
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance studyDaisuke Yabe, Fumiko Yamamoto, Søren S Lund, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trialsSøren S Lund, Naveed Sattar, Afshin Salsali, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme|December 7, 2007
Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?Allan Vaag, Søren S Lund
Clinical Chemistry|July 2, 2011
Using nonfasting lipids--hemodilution or convenience?Søren S Lund, Tonny Jensen
Diabetes Care|July 1, 2009
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et alSøren S Lund, Allan A Vaag
European Journal of Endocrinology|September 21, 2011
Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesAllan Vaag, Søren S Lund, Sørens Lund
Ugeskrift for Laeger|May 8, 2009
[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes]Bianca Hemmingsen, Søren S Lund, Allan Vaag
The New England Journal of Medicine|January 24, 2009
Follow-up of intensive glucose control in type 2 diabetesSøren S Lund, Peter Rossing, Allan A Vaag
Circulation|April 8, 2009
Letter by Lund et al regarding article, "fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events"Søren S Lund, Allan A Vaag, Tonny Jensen
European Journal of Endocrinology|April 17, 2009
Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetesBianca Hemmingsen, Søren S Lund, Jørn Wetterslev, et al.
Expert Opinion on Drug Safety|April 14, 2022
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance studyDaisuke Yabe, Fumiko Yamamoto, Søren S Lund, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trialsSøren S Lund, Naveed Sattar, Afshin Salsali, et al.
Pageof 5